CoChat
Sign Up
Cited by 416

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Hybrid exosomes, exosome-like nanovesicles and engineered exosomes for therapeutic applications

Mondal, Jagannath, Pillarisetti, Shameer, Junnuthula, Vijayabhaskarreddy, Saha, Monochura, Hwang, Seung Rim, Park, In-kyu, Lee, Yong-kyu·2023·Journal of Controlled Release
DOI 10.1016/j.jconrel.2022.12.027
Open this paper in CoChat — free account

Abstract

Exosomes are endosome-derived nanovesicles involved in cellular communication. They are natural nanocarriers secreted by various cells, making them suitable candidates for diverse drug delivery and therapeutic applications from a material standpoint. They have a phospholipid bilayer decorated with functional molecules and an enclosed parental matrix, which has attracted interest in developing designer/hybrid engineered exosome nanocarriers. The structural versatility of exosomes allows the modification of their original configuration using various methods, including genetic engineering, chemical procedures, physical techniques, and microfluidic technology, to load exosomes with additional cargo for expanded biomedical applications. Exosomes show enormous potential for overcoming the limitations of conventional nanoparticle-based techniques in targeted therapy. This review highlights the exosome sources, characteristics, state of the art in the field of hybrid exosomes, exosome-like nanovesicles and engineered exosomes as potential cargo delivery vehicles for therapeutic applications.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2022.12.027

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 17 references

Research works printed but not linked: 215

  1. Lim, 2015, Nanomaterials for theranostics: recent advances and future challenges, Chem. Rev., 115, 327, 10.1021/cr300213b · DOI
  2. Junnuthula, 2022, Polymeric micelles for breast cancer therapy: recent updates, clinical translation and regulatory considerations., Pharmaceutics, 14, 1860, 10.3390/pharmaceutics14091860 · DOI
  3. Li, 2012, Mesoporous silica nanoparticles in biomedical applications, Chem. Soc. Rev., 41, 2590, 10.1039/c1cs15246g · DOI
  4. Yu, 2020, Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs, Nat. Biomed. Eng., 4, 499, 10.1038/s41551-019-0508-y · DOI · Paper page
  5. Ridolfo, 2020, Exploring the impact of morphology on the properties of biodegradable nanoparticles and their diffusion in complex biological medium, Biomacromolecules, 22, 126, 10.1021/acs.biomac.0c00726 · DOI
  6. Chen, 2015, Two-dimensional graphene analogues for biomedical applications, Chem. Soc. Rev., 44, 2681, 10.1039/C4CS00300D · DOI
  7. Xu, 2020, Temperature-responsive multilayer films of micelle-based composites for controlled release of a third-generation EGFR inhibitor, ACS Appl. Polym. Mater., 2, 741, 10.1021/acsapm.9b01051 · DOI
  8. Xu, 2021, Temperature-responsive multilayer films based on block copolymer-coated silica nanoparticles for long-term release of favipiravir, ACS Appl. Nano Mater., 4, 14014, 10.1021/acsanm.1c03334 · DOI
  9. Xu, 2022, Steric effects in the deposition mode and drug-delivering efficiency of nanocapsule-based multilayer films, ACS Omega, 7, 30321, 10.1021/acsomega.2c03591 · DOI
  10. Xu, 2019, Electrostatically assembled multilayered films of biopolymer enhanced nanocapsules for on-demand drug release, ACS Appl. Bio Mater., 2, 3429, 10.1021/acsabm.9b00381 · DOI
  11. Rayamajhi, 2019, Macrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery, Acta Biomater., 94, 482, 10.1016/j.actbio.2019.05.054 · DOI · Paper page
  12. Min, 2015, Clinical translation of nanomedicine, Chem. Rev., 115, 11147, 10.1021/acs.chemrev.5b00116 · DOI
  13. Peng, 2016, The potential of protein–nanomaterial interaction for advanced drug delivery, J. Control. Release, 225, 121, 10.1016/j.jconrel.2016.01.041 · DOI · Paper page
  14. Batrakova, 2015, Using exosomes, naturally-equipped nanocarriers, for drug delivery, J. Control. Release, 219, 396, 10.1016/j.jconrel.2015.07.030 · DOI · Paper page
  15. Colombo, 2014, Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles, Annu. Rev. Cell Dev. Biol., 30, 255, 10.1146/annurev-cellbio-101512-122326 · DOI · Paper page
  16. Peng, 2020, Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-TRAIL–programmed therapy against melanoma, Sci. Adv., 6, 10.1126/sciadv.aba2735 · DOI
  17. Lee, 2022, Exosome-based drug delivery systems and their therapeutic applications, RSC Adv., 12, 18475, 10.1039/D2RA02351B · DOI
  18. Rupert, 2017, Methods for the physical characterization and quantification of extracellular vesicles in biological samples, Biochim. Biophys. Acta (BBA), 1861, 3164, 10.1016/j.bbagen.2016.07.028 · DOI
  19. Din, 2017, Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors, Int. J. Nanomedicine, 12, 7291, 10.2147/IJN.S146315 · DOI
  20. Kooijmans, 2012, Exosome mimetics: a novel class of drug delivery systems, Int. J. Nanomedicine, 7, 1525
  21. Aqil, 2016, Exosomal formulation enhances therapeutic response of celastrol against lung cancer, Exp. Mol. Pathol., 101, 12, 10.1016/j.yexmp.2016.05.013 · DOI
  22. Zhang, 2012, Exosomes and immune surveillance of neoplastic lesions: a review, Biotech. Histochem., 87, 161, 10.3109/10520291003659042 · DOI
  23. Mosquera-Heredia, 2021, Exosomes: potential disease biomarkers and new therapeutic targets, Biomedicines, 9, 1061, 10.3390/biomedicines9081061 · DOI
  24. Kim, 2021, Recent advances in exosome-based drug delivery for cancer therapy, Cancers, 13, 4435, 10.3390/cancers13174435 · DOI · Paper page
  25. Choi, 2022, Targeted delivery of exosomes armed with anti-cancer therapeutics, Membranes, 12, 85, 10.3390/membranes12010085 · DOI
  26. Antimisiaris, 2018, Exosomes and exosome-inspired vesicles for targeted drug delivery, Pharmaceutics, 10, 218, 10.3390/pharmaceutics10040218 · DOI
  27. Cheng, 2017, Focus on mesenchymal stem cell-derived exosomes: opportunities and challenges in cell-free therapy, Stem Cells Int., 2017, 6305295, 10.1155/2017/6305295 · DOI
  28. Zhong, 2021, High-quality milk exosomes as oral drug delivery system, Biomaterials, 277, 10.1016/j.biomaterials.2021.121126 · DOI
  29. Wang, 2013, Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids, Nat. Commun., 4, 1, 10.1038/ncomms3358 · DOI
  30. Manca, 2018, Milk exosomes are bioavailable and distinct microRNA cargos have unique tissue distribution patterns, Sci. Rep., 8, 11321, 10.1038/s41598-018-29780-1 · DOI
  31. Wijenayake, 2021, Comparison of methods for pre-processing, exosome isolation, and RNA extraction in unpasteurized bovine and human milk, PLoS One, 16, 10.1371/journal.pone.0257633 · DOI
  32. Sánchez, 2021, Breast milk: a source of functional compounds with potential application in nutrition and therapy, Nutrients, 13, 1026, 10.3390/nu13031026 · DOI
  33. Marsh, 2021, Novel protocols for scalable production of high quality purified small extracellular vesicles from bovine milk, Nanotheranostics, 5, 488, 10.7150/ntno.62213 · DOI
  34. Yang, 2018, Microbe-derived extracellular vesicles as a smart drug delivery system, Transl. Clin. Pharmacol., 26, 103, 10.12793/tcp.2018.26.3.103 · DOI
  35. Lotvall, 2014, Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles, J. Extracell. Ves., 3, 10.3402
  36. Reddy, 2018, 23, 441
  37. Lamparski, 2002, Production and characterization of clinical grade exosomes derived from dendritic cells, J. Immunol. Methods, 270, 211, 10.1016/S0022-1759(02)00330-7 · DOI
  38. Contreras-Naranjo, 2017, Microfluidics for exosome isolation and analysis: enabling liquid biopsy for personalized medicine, Lab Chip, 17, 3558, 10.1039/C7LC00592J · DOI
  39. Jalaludin, 2021, MALDI-MS: a powerful but underutilized mass spectrometric technique for exosome research, Mass Spectrom. Lett., 12, 93
  40. Ye, 2021, Nucleic acids and proteins carried by exosomes of different origins as potential biomarkers for gynecologic cancers, Mol. Ther. Oncol., 24, 101, 10.1016/j.omto.2021.12.005 · DOI
  41. Huda, 2021, Potential use of exosomes as diagnostic biomarkers and in targeted drug delivery: progress in clinical and preclinical applications, ACS Biomater. Sci. Eng., 7, 2106, 10.1021/acsbiomaterials.1c00217 · DOI
  42. Kurian, 2021, Elucidating methods for isolation and quantification of exosomes: a review, Mol. Biotechnol., 63, 249, 10.1007/s12033-021-00300-3 · DOI
  43. Zhou, 2020, Methods for exosome isolation and characterization, Exosomes, 23, 10.1016/B978-0-12-816053-4.00002-X · DOI
  44. Beit-Yannai, 2018, Physical exosome: exosome interactions, J. Cell. Mol. Med., 22, 2001, 10.1111/jcmm.13479 · DOI
  45. Kim, 2021, Plant-derived exosome-like nanoparticles and their therapeutic activities, Asian J. Pharm. Sci., 17, 53
  46. Li, 2018, Arrowtail RNA for ligand display on ginger exosome-like nanovesicles to systemic deliver siRNA for cancer suppression, Sci. Rep., 8, 1
  47. Webber, 2013, How pure are your vesicles?, J. Extracell. Ves., 2, 19861, 10.3402/jev.v2i0.19861 · DOI · Paper page
  48. Gutwein, 2005, Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells, Clin. Cancer Res., 11, 2492, 10.1158/1078-0432.CCR-04-1688 · DOI
  49. Ingato, 2016, Good things come in small packages: overcoming challenges to harness extracellular vesicles for therapeutic delivery, J. Control. Release, 241, 174, 10.1016/j.jconrel.2016.09.016 · DOI
  50. Watt, 2009, N-terminal domains elicit formation of functional Pmel17 amyloid fibrils, J. Biol. Chem., 284, 35543, 10.1074/jbc.M109.047449 · DOI
  51. Stremersch, 2016, Therapeutic and diagnostic applications of extracellular vesicles, J. Control. Release, 244, 167, 10.1016/j.jconrel.2016.07.054 · DOI
  52. Teng, 2018, Plant-derived exosomal microRNAs shape the gut microbiota, Cell Host Microbe, 24, 637, 10.1016/j.chom.2018.10.001 · DOI · Paper page
  53. Deng, 2017, Broccoli-derived nanoparticle inhibits mouse colitis by activating dendritic cell AMP-activated protein kinase, Mol. Ther., 25, 1641, 10.1016/j.ymthe.2017.01.025 · DOI
  54. Zhang, 2016, Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer, Biomaterials, 101, 321, 10.1016/j.biomaterials.2016.06.018 · DOI
  55. He, 2020, Curcumin-laden exosomes target ischemic brain tissue and alleviate cerebral ischemia-reperfusion injury by inhibiting ROS-mediated mitochondrial apoptosis, Mater. Sci. Eng. C, 117, 10.1016/j.msec.2020.111314 · DOI
  56. Wang, 2019, Exosomes from M1-polarized macrophages enhance paclitaxel antitumor activity by activating macrophages-mediated inflammation, Theranostics, 9, 1714, 10.7150/thno.30716 · DOI · Paper page
  57. Sun, 2016, Safety evaluation of exosomes derived from human umbilical cord mesenchymal stromal cell, Cytotherapy, 18, 413, 10.1016/j.jcyt.2015.11.018 · DOI
  58. Yang, 2021, Eradicating intracellular MRSA via targeted delivery of lysostaphin and vancomycin with mannose-modified exosomes, J. Control. Release, 329, 454, 10.1016/j.jconrel.2020.11.045 · DOI
  59. Segura, 2005, Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses, Blood Cell Mol. Dis., 35, 89, 10.1016/j.bcmd.2005.05.003 · DOI
  60. Cao, 2022, Mesenchymal stem cell-derived exosomes: toward cell-free therapeutic strategies in chronic kidney disease, Front. Med., 9, 10.3389/fmed.2022.816656 · DOI
  61. Giassafaki, 2021, Towards analyzing the potential of exosomes to deliver microRNA therapeutics, J. Cell. Physiol., 236, 1529, 10.1002/jcp.29991 · DOI
  62. Cho, 2017, Comparison of intra-articular lumbar facet joint pulsed radiofrequency and intra-articular lumbar facet joint corticosteroid injection for management of lumbar facet joint pain: a randomized controlled trial (vol 96, e6524, 2016), Medicine, 96
  63. Alzahrani, 2019, Melatonin improves therapeutic potential of mesenchymal stem cells-derived exosomes against renal ischemia-reperfusion injury in rats, Am. J. Transl. Res., 11, 2887
  64. Wang, 2020, A new self-healing hydrogel containing hucMSC-derived exosomes promotes bone regeneration, Front. Bioeng. Biotechnol., 1047
  65. Vig, 2022, Bone cell exosomes and emerging strategies in bone engineering, Biomedicines, 10, 767, 10.3390/biomedicines10040767 · DOI
  66. Li, 2020, Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer, Acta Biomater., 101, 519, 10.1016/j.actbio.2019.10.022 · DOI
  67. Bunggulawa, 2018, Recent advancements in the use of exosomes as drug delivery systems, J. Nanobiotechnol., 16, 1, 10.1186/s12951-018-0403-9 · DOI
  68. Sun, 2016, Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity, Cell Discov., 2, 1, 10.1038/celldisc.2016.15 · DOI
  69. Tran, 2019, Aspirin-loaded nanoexosomes as cancer therapeutics, Int. J. Pharm., 572, 10.1016/j.ijpharm.2019.118786 · DOI
  70. Zhao, 2020, Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis, J. Control. Release, 318, 1, 10.1016/j.jconrel.2019.12.005 · DOI
  71. Gujrati, 2014, Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy, ACS Nano, 8, 1525, 10.1021/nn405724x · DOI
  72. Alves, 2015, Bacterial nanobioreactors–directing enzyme packaging into bacterial outer membrane vesicles, ACS Appl. Mater. Interfaces, 7, 24963, 10.1021/acsami.5b08811 · DOI
  73. Huang, 2020, Development of novel nanoantibiotics using an outer membrane vesicle-based drug efflux mechanism, J. Control. Release, 317, 1, 10.1016/j.jconrel.2019.11.017 · DOI
  74. Kuerban, 2020, Doxorubicin-loaded bacterial outer-membrane vesicles exert enhanced anti-tumor efficacy in non-small-cell lung cancer, Acta Pharm. Sin. B, 10, 1534, 10.1016/j.apsb.2020.02.002 · DOI
  75. Ferreira, 2022, LAMP2A regulates the loading of proteins into exosomes, Sci. Adv., 8, 10.1126/sciadv.abm1140 · DOI
  76. Gupta, 2021, Dosing extracellular vesicles, Adv. Drug Deliv. Rev., 178, 10.1016/j.addr.2021.113961 · DOI
  77. Munagala, 2016, Bovine milk-derived exosomes for drug delivery, Cancer Lett., 371, 48, 10.1016/j.canlet.2015.10.020 · DOI
  78. Agrawal, 2017, Milk-derived exosomes for oral delivery of paclitaxel, Nanomedicine: Nanotechnology, Biol. Med., 13, 1627
  79. Aqil, 2017, Exosomes for the enhanced tissue bioavailability and efficacy of curcumin, AAPS J., 19, 1691, 10.1208/s12248-017-0154-9 · DOI
  80. Chen, 2019, Exosome-like nanoparticles from ginger rhizomes inhibited NLRP3 inflammasome activation, Mol. Pharm., 16, 2690, 10.1021/acs.molpharmaceut.9b00246 · DOI
  81. Zhang, 2016, Edible ginger-derived nano-lipids loaded with doxorubicin as a novel drug-delivery approach for colon cancer therapy, Mol. Ther., 24, 1783, 10.1038/mt.2016.159 · DOI
  82. Wang, 2015, Grapefruit-derived nanovectors use an activated leukocyte trafficking pathway to deliver therapeutic agents to inflammatory tumor sites, Cancer Res., 75, 2520, 10.1158/0008-5472.CAN-14-3095 · DOI
  83. Karaosmanoğlu, 2019, Investigation of the cytotoxicity of fig, lemon, olive, and turnip exosomes on MCF-7 cells, Kahramanmaraş Sütçü İmam Üniversitesi Tarım Doğa Dergisi, 22, 382, 10.18016/ksutarimdoga.v22i49454.589845 · DOI
  84. Perut, 2021, Strawberry-derived exosome-like nanoparticles prevent oxidative stress in human mesenchymal stromal cells, Biomolecules, 11, 87, 10.3390/biom11010087 · DOI
  85. Agrawal, 2014, Is nanotechnology a boon for oral drug delivery?, Drug Discov. Today, 19, 1530, 10.1016/j.drudis.2014.04.011 · DOI
  86. Sharma, 2021, Toxicology of nanoparticles in drug delivery, Curr. Pathobiol. Rep., 1
  87. van Dommelen, 2012, Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery, J. Control. Release, 161, 635, 10.1016/j.jconrel.2011.11.021 · DOI
  88. Li, 2017, Progress in exosome isolation techniques, Theranostics, 7, 789, 10.7150/thno.18133 · DOI
  89. Li, 2019, Nitroimidazole derivative incorporated liposomes for hypoxia-triggered drug delivery and enhanced therapeutic efficacy in patient-derived tumor xenografts, Acta Biomater., 83, 334, 10.1016/j.actbio.2018.10.029 · DOI
  90. Liu, 2022, Research progress in membrane fusion-based hybrid exosomes for drug delivery systems, Front. Bioeng. Biotechnol., 10
  91. Li, 2021, Artificial exosomes for translational nanomedicine, J. Nanobiotechnol., 19, 242, 10.1186/s12951-021-00986-2 · DOI · Paper page
  92. Goh, 2018, EXOPLEXs: chimeric drug delivery platform from the fusion of cell-derived nanovesicles and liposomes, Biomacromolecules, 19, 22, 10.1021/acs.biomac.7b01176 · DOI
  93. Piffoux, 2018, Modification of extracellular vesicles by fusion with liposomes for the design of personalized biogenic drug delivery systems, ACS Nano, 12, 6830, 10.1021/acsnano.8b02053 · DOI
  94. Nelson, 2016, In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy, Science, 351, 403, 10.1126/science.aad5143 · DOI · Paper page
  95. Ma, 2021, Depletion of glioma stem cells by synergistic inhibition of mTOR and c-Myc with a biological camouflaged cascade brain-targeting nanosystem, Biomaterials, 268, 10.1016/j.biomaterials.2020.120564 · DOI
  96. Li, 2022, Overcoming the blood-brain barrier: Exosomes as theranostic nanocarriers for precision neuroimaging, J. Control. Release, 349, 902, 10.1016/j.jconrel.2022.08.002 · DOI
  97. Martinez-Lostao, 2010, Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis, Arthritis, Rheumatol., 62, 2272
  98. Choi, 2019, Mannose-modified serum exosomes for the elevated uptake to murine dendritic cells and lymphatic accumulation, Macromol. Biosci., 19, 1900042, 10.1002/mabi.201900042 · DOI
  99. Hu, 2021, Immunogenic hybrid nanovesicles of liposomes and tumor-derived nanovesicles for cancer immunochemotherapy, ACS Nano, 15, 3123, 10.1021/acsnano.0c09681 · DOI
  100. Yang, 2019, Exosome biochemistry and advanced nanotechnology for next-generation theranostic platforms, Adv. Mater., 31, 1802896, 10.1002/adma.201802896 · DOI · Paper page
  101. Kimiz-Gebologlu, 2022, Exosomes: Large-scale production, isolation, drug loading efficiency, and biodistribution and uptake, J. Control. Release, 347, 533, 10.1016/j.jconrel.2022.05.027 · DOI · Paper page
  102. Rayamajhi, 2019, Macrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery, Acta Biomater., 94, 482, 10.1016/j.actbio.2019.05.054 · DOI · Paper page
  103. Lin, 2018, Exosome–liposome hybrid nanoparticles deliver CRISPR/Cas9 system in MSCs, Adv. Sci., 5, 1700611, 10.1002/advs.201700611 · DOI · Paper page
  104. Hu, 2021, Immunogenic hybrid nanovesicles of liposomes and tumor-derived nanovesicles for cancer immunochemotherapy, ACS Nano, 15, 3123, 10.1021/acsnano.0c09681 · DOI
  105. Han, 2022, Exosome-like nanovesicles derived from Phellinus linteus inhibit Mical2 expression through cross-kingdom regulation and inhibit ultraviolet-induced skin aging, J. Nanobiotechnol., 20, 1, 10.1186/s12951-022-01657-6 · DOI
  106. Dad, 2021, Plant exosome-like nanovesicles: emerging therapeutics and drug delivery nanoplatforms, Mol. Ther., 29, 13, 10.1016/j.ymthe.2020.11.030 · DOI
  107. Mu, 2014, Interspecies communication between plant and mouse gut host cells through edible plant derived exosome-like nanoparticles, Mol. Nutr. Food Res., 58, 1561, 10.1002/mnfr.201300729 · DOI
  108. Fernandes, 2020, Exosome-like nanoparticles: a new type of nanocarrier, Curr. Med. Chem., 27, 3888, 10.2174/0929867326666190129142604 · DOI · Paper page
  109. Liu, 2022, Engineered extracellular vesicles and their mimetics for cancer immunotherapy, J. Control. Release, 349, 679, 10.1016/j.jconrel.2022.05.062 · DOI
  110. Alvarez-Erviti, 2011, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes, Nat. Biotechnol., 29, 341, 10.1038/nbt.1807 · DOI · Paper page
  111. Barile, 2017, Exosomes: therapy delivery tools and biomarkers of diseases, Pharmacol. Ther., 174, 63, 10.1016/j.pharmthera.2017.02.020 · DOI
  112. Hung, 2015, Stabilization of exosome-targeting peptides via engineered glycosylation, J. Biol. Chem., 290, 8166, 10.1074/jbc.M114.621383 · DOI
  113. Stickney, 2016, Development of exosome surface display technology in living human cells, Biochem. Biophys. Res. Commun., 472, 53, 10.1016/j.bbrc.2016.02.058 · DOI
  114. Kooijmans, 2016, Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting, J. Extracell. Ves., 5, 31053, 10.3402/jev.v5.31053 · DOI
  115. Ohno, 2013, Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells, Mol. Ther., 21, 185, 10.1038/mt.2012.180 · DOI · Paper page
  116. Rountree, 2011, Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy, Cancer Res., 71, 5235, 10.1158/0008-5472.CAN-10-4076 · DOI
  117. Mentkowski, 2018, Therapeutic potential of engineered extracellular vesicles, AAPS J., 20, 1, 10.1208/s12248-018-0211-z · DOI
  118. Meyer, 2017, Pseudotyping exosomes for enhanced protein delivery in mammalian cells, Int. J. Nanomedicine, 12, 3153, 10.2147/IJN.S133430 · DOI
  119. Trivedi, 2016, Modification of tumor cell exosome content by transfection with wt-p53 and microRNA-125b expressing plasmid DNA and its effect on macrophage polarization, Oncogenesis, 5, 10.1038/oncsis.2016.52 · DOI
  120. Su, 2016, Pancreatic cancer cell exosome-mediated macrophage reprogramming and the role of microRNAs 155 and 125b2 transfection using nanoparticle delivery systems, Sci. Rep., 6, 1
  121. Zhang, 2018, Genetically engineered liposome-like nanovesicles as active targeted transport platform, Adv. Biomater., 30, 1705350
  122. Cheng, 2021, Expanding the toolbox of exosome-based modulators of cell functions, Biomaterials, 277, 10.1016/j.biomaterials.2021.121129 · DOI
  123. Jia, 2018, NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo, Biomaterials, 178, 302, 10.1016/j.biomaterials.2018.06.029 · DOI · Paper page
  124. Khosravi, 2022, Stem cell membrane, stem cell-derived exosomes and hybrid stem cell camouflaged nanoparticles: A promising biomimetic nanoplatforms for cancer theranostics, J. Control. Release, 348, 706, 10.1016/j.jconrel.2022.06.026 · DOI
  125. Uthaman, 2022, Nanomaterials for natural killer cell-based immunoimaging and immunotherapies in cancer, ACS Appl. Mater. Interfaces
  126. Koh, 2017, Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis, Biomaterials, 121, 121, 10.1016/j.biomaterials.2017.01.004 · DOI
  127. Kim, 2018, Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations, Nanomedicine: Nanotechnology, Biol. Med., 14, 195
  128. Park, 2022, Regulation of in vivo fate of exosomes for therapeutic applications: New frontier in nanomedicines, J. Control. Release, 348, 483, 10.1016/j.jconrel.2022.05.058 · DOI
  129. Cao, 2019, Engineered exosome-mediated near-infrared-II region V2C quantum dot delivery for nucleus-target low-temperature photothermal therapy, ACS Nano, 13, 1499
  130. Pi, 2018, Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression, Nat. Nanotechnol., 13, 82, 10.1038/s41565-017-0012-z · DOI
  131. Wang, 2017, Nucleolin-targeted extracellular vesicles as a versatile platform for biologics delivery to breast cancer, Theranostics, 7, 1360, 10.7150/thno.16532 · DOI
  132. Zhang, 2020, Bio-engineered cell membrane nanovesicles as precision theranostics for perihilar cholangiocarcinoma, Biomater. Sci., 8, 1575, 10.1039/C9BM02088H · DOI
  133. Arntz, 2015, Oral administration of bovine milk derived extracellular vesicles attenuates arthritis in two mouse models, Mol. Nutr. Food Res., 59, 1701, 10.1002/mnfr.201500222 · DOI
  134. Zou, 2019, Aptamer-functionalized exosomes: elucidating the cellular uptake mechanism and the potential for cancer-targeted chemotherapy, Anal. Chem., 91, 2425, 10.1021/acs.analchem.8b05204 · DOI
  135. Wan, 2018, Aptamer-conjugated extracellular nanovesicles for targeted drug delivery, Cancer Res., 78, 798, 10.1158/0008-5472.CAN-17-2880 · DOI
  136. Lathwal, 2021, Engineering exosome polymer hybrids by atom transfer radical polymerization, Proc. Natl. Acad. Sci., 118, 10.1073/pnas.2020241118 · DOI
  137. Munagala, 2021, Exosome-mediated delivery of RNA and DNA for gene therapy, Cancer Lett., 505, 58, 10.1016/j.canlet.2021.02.011 · DOI
  138. Sawada, 2020, Nanogel hybrid assembly for exosome intracellular delivery: effects on endocytosis and fusion by exosome surface polymer engineering, Biomater. Sci., 8, 619, 10.1039/C9BM01232J · DOI
  139. Lee, 2021, Exosomes and cancer stem cells in cancer immunity: current reports and future directions, Vaccines, 9, 441, 10.3390/vaccines9050441 · DOI
  140. Cheng, 2016, Targeting soluble proteins to exosomes using a ubiquitin tag, Biotechnol. Bioeng., 113, 1315, 10.1002/bit.25884 · DOI
  141. Huang, 2022, Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy, J. Control. Release, 343, 107, 10.1016/j.jconrel.2022.01.026 · DOI · Paper page
  142. Ortega, 2020, Exosomes as drug delivery systems: endogenous nanovehicles for treatment of systemic lupus erythematosus, Pharmaceutics, 13, 3, 10.3390/pharmaceutics13010003 · DOI
  143. Yong, 2020, Extracellular vesicles-based drug delivery systems for cancer immunotherapy, J. Control. Release, 328, 562, 10.1016/j.jconrel.2020.09.028 · DOI
  144. Xiao, 2012, Proteomic analysis of microvesicles in human saliva by gel electrophoresis with liquid chromatography-mass spectrometry, Anal. Chim. Acta, 723, 61, 10.1016/j.aca.2012.02.018 · DOI
  145. Li, 2022, M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization, J. Control. Release, 341, 16, 10.1016/j.jconrel.2021.11.019 · DOI
  146. Hao, 2007, Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity, Immunology, 120, 90, 10.1111/j.1365-2567.2006.02483.x · DOI
  147. Segura, 2005, ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming, Blood, 106, 216, 10.1182/blood-2005-01-0220 · DOI
  148. Gao, 2016, Exosomes derived from mature dendritic cells increase endothelial inflammation and atherosclerosis via membrane TNF-α mediated NF-κB pathway, J. Cell. Mol. Med., 20, 2318, 10.1111/jcmm.12923 · DOI
  149. Lamichhane, 2015, Exogenous DNA loading into extracellular vesicles via electroporation is size-dependent and enables limited gene delivery, Mol. Pharm., 12, 3650, 10.1021/acs.molpharmaceut.5b00364 · DOI
  150. Santos, 2018, VAMP-associated protein-A and oxysterol-binding protein–related protein 3 promote the entry of late endosomes into the nucleoplasmic reticulum, J. Biol. Chem., 293, 13834, 10.1074/jbc.RA118.003725 · DOI
  151. Dad, 2020, Plant exosome like nanovesicles: Emerging therapeutics and drug delivery nanoplatforms, Mol. Ther., 29, 13, 10.1016/j.ymthe.2020.11.030 · DOI
  152. Iravani, 2019, Plant-derived edible nanoparticles and miRNAs: emerging frontier for therapeutics and targeted drug-delivery, ACS Sustain. Chem. Eng., 7, 8055, 10.1021/acssuschemeng.9b00954 · DOI
  153. Nakase, 2016, Vectorization of biomacromolecules into cells using extracellular vesicles with enhanced internalization induced by macropinocytosis, Sci. Rep., 6, 1, 10.1038/srep34937 · DOI
  154. Yang, 2017, Virus-mimetic fusogenic exosomes for direct delivery of integral membrane proteins to target cell membranes, Adv. Mater., 29, 1605604, 10.1002/adma.201605604 · DOI
  155. Lu, 2019, Cell-free synthesis of connexin 43-integrated exosome-mimetic nanoparticles for siRNA delivery, Acta Biomater., 96, 517, 10.1016/j.actbio.2019.07.006 · DOI
  156. Horibe, 2018, Mechanism of recipient cell-dependent differences in exosome uptake, BMC Cancer, 18, 1, 10.1186/s12885-017-3958-1 · DOI
  157. Longatti, 2018, High affinity single-chain variable fragments are specific and versatile targeting motifs for extracellular vesicles, Nanoscale, 10, 14230, 10.1039/C8NR03970D · DOI
  158. Di, 2018, Exosomes as drug carriers for clinical application, Artif. Cells Nanomed. Biotechnol., 46, S564, 10.1080/21691401.2018.1501381 · DOI
  159. Shao, 2020, Advances in exosome-based drug delivery and tumor targeting: from tissue distribution to intracellular fate, Int. J. Nanomedicine, 15, 9355, 10.2147/IJN.S281890 · DOI · Paper page
  160. García-Manrique, 2018, Therapeutic biomaterials based on extracellular vesicles: classification of bio-engineering and mimetic preparation routes, J. Extracell. Ves., 7, 1422676, 10.1080/20013078.2017.1422676 · DOI
  161. Kučuk, 2021, Exosomes engineering and their roles as therapy delivery tools, therapeutic targets, and biomarkers, Int. J. Mol. Sci., 22, 9543, 10.3390/ijms22179543 · DOI
  162. Liu, 2019, Design strategies and application progress of therapeutic exosomes, Theranostics, 9, 1015, 10.7150/thno.30853 · DOI
  163. Smyth, 2015, Biodistribution and delivery efficiency of unmodified tumor-derived exosomes, J. Control. Release, 199, 145, 10.1016/j.jconrel.2014.12.013 · DOI
  164. Gangadaran, 2020, Extracellular vesicle-and extracellular vesicle mimetics-based drug delivery systems: new perspectives, challenges, and clinical developments, Pharmaceutics, 12, 442, 10.3390/pharmaceutics12050442 · DOI
  165. Wang, 2018, Designer exosomes for active targeted chemo-photothermal synergistic tumor therapy, Adv. Funct. Mater., 28, 1707360, 10.1002/adfm.201707360 · DOI
  166. Aryani, 2016, Exosomes as a nanodelivery system: a key to the future of neuromedicine?, Mol. Neurobiol., 53, 818, 10.1007/s12035-014-9054-5 · DOI
  167. Muralidharan-Chari, 2010, Microvesicles: mediators of extracellular communication during cancer progression, J. Cell Sci., 123, 1603, 10.1242/jcs.064386 · DOI
  168. Lai, 2020, Systemic exosomal miR-193b-3p delivery attenuates neuroinflammation in early brain injury after subarachnoid hemorrhage in mice, J. Neuroinflammation, 17, 1, 10.1186/s12974-020-01745-0 · DOI · Paper page
  169. Bashyal, 2022, Recent progresses in exosome-based systems for targeted drug delivery to the brain, J. Control. Release, 348, 723, 10.1016/j.jconrel.2022.06.011 · DOI
  170. Yang, 2015, Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio, Pharm. Res., 32, 2003, 10.1007/s11095-014-1593-y · DOI
  171. Sokolova, 2011, The www as a habitat, Белорусский ежегодник, 146
  172. Tian, 2014, A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy, Biomaterials, 35, 2383, 10.1016/j.biomaterials.2013.11.083 · DOI
  173. Tian, 2018, Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy, Biomaterials, 150, 137, 10.1016/j.biomaterials.2017.10.012 · DOI · Paper page
  174. He, 2021, Exosomal targeting and its potential clinical application, Drug Deliv. Transl. Res., 1
  175. Cheng, 2019, Chimeric peptide engineered exosomes for dual-stage light guided plasma membrane and nucleus targeted photodynamic therapy, Biomaterials, 211, 14, 10.1016/j.biomaterials.2019.05.004 · DOI
  176. Takahashi, 2013, Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection, J. Biotechnol., 165, 77, 10.1016/j.jbiotec.2013.03.013 · DOI
  177. Delcayre, 2005, Exosome display technology: applications to the development of new diagnostics and therapeutics, Blood Cell Mol. Dis., 35, 158, 10.1016/j.bcmd.2005.07.003 · DOI
  178. Cui, 2019, RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer’s disease, Immun. Ageing, 16, 1, 10.1186/s12979-019-0150-2 · DOI
  179. Ye, 2018, Methotrexate-loaded extracellular vesicles functionalized with therapeutic and targeted peptides for the treatment of glioblastoma multiforme, ACS Appl. Mater. Interfaces, 10, 12341, 10.1021/acsami.7b18135 · DOI
  180. Nie, 2020, Responsive exosome nano-bioconjugates for synergistic cancer therapy, Angew. Chem., 132, 2034, 10.1002/ange.201912524 · DOI
  181. Wang, 2017, The use of RGD-engineered exosomes for enhanced targeting ability and synergistic therapy toward angiogenesis, Nanoscale, 9, 15598, 10.1039/C7NR04425A · DOI
  182. Wang, 2018, Engineered exosomes with ischemic myocardium-targeting peptide for targeted therapy in myocardial infarction, J. Am. Heart Assoc., 7, 10.1161/JAHA.118.008737 · DOI
  183. Zhou, 2019, Tumor-specific delivery of KRAS siRNA with iRGD-exosomes efficiently inhibits tumor growth, ExRNA, 1, 1, 10.1186/s41544-019-0034-9 · DOI
  184. Mentkowski, 2019, Exosomes engineered to express a cardiomyocyte binding peptide demonstrate improved cardiac retention in vivo, Sci. Rep., 9, 1, 10.1038/s41598-019-46407-1 · DOI · Paper page
  185. Bellavia, 2017, Interleukin 3-receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth, Theranostics, 7, 1333, 10.7150/thno.17092 · DOI · Paper page
  186. Bobrie, 2011, Exosome secretion: molecular mechanisms and roles in immune responses, Traffic, 12, 1659, 10.1111/j.1600-0854.2011.01225.x · DOI
  187. Kerr, 2006, Visualisation of macropinosome maturation by the recruitment of sorting nexins, J. Cell Sci., 119, 3967, 10.1242/jcs.03167 · DOI
  188. Hewlett, 1994, The coated pit and macropinocytic pathways serve distinct endosome populations, J. Cell Biol., 124, 689, 10.1083/jcb.124.5.689 · DOI
  189. Gurung, 2021, The exosome journey: from biogenesis to uptake and intracellular signalling, Cell Commun. Signal., 19, 1, 10.1186/s12964-021-00730-1 · DOI
  190. Fitzner, 2011, Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis, J. Cell Sci., 124, 447, 10.1242/jcs.074088 · DOI · Paper page
  191. Haney, 2015, Exosomes as drug delivery vehicles for Parkinson's disease therapy, J. Control. Release, 207, 18, 10.1016/j.jconrel.2015.03.033 · DOI · Paper page
  192. Théry, 2009, Membrane vesicles as conveyors of immune responses, Nat. Rev. Immunol., 9, 581, 10.1038/nri2567 · DOI
  193. Rana, 2012, Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection, Int. J. Biochem. Cell Biol., 44, 1574, 10.1016/j.biocel.2012.06.018 · DOI
  194. Spuch, 2011, Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer's disease and Parkinson's disease), J. Drug Deliv., 2011, 10.1155/2011/469679 · DOI · Paper page
  195. Kucherianu, 1997, The effect of liposomal form of L-Dopa on the development of parkinsonian syndrome in mice, Biulleten'eksperimental'noi biologii i meditsiny, 123, 29
  196. Chiu, 2016, A single-cell assay for time lapse studies of exosome secretion and cell behaviors, Small, 12, 3658, 10.1002/smll.201600725 · DOI
  197. Li, 2015, Serum-free culture alters the quantity and protein composition of neuroblastoma-derived extracellular vesicles, J. Extracell. Ves., 4, 26883, 10.3402/jev.v4.26883 · DOI
  198. Bost, 2022, Growth media conditions influence the secretion route and release levels of engineered extracellular vesicles, Adv. Healthc. Mater., 11, 2101658, 10.1002/adhm.202101658 · DOI
  199. Lee, 2011, Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects, Exp. Mol. Med., 43, 281, 10.3858/emm.2011.43.5.029 · DOI
  200. Bryniarski, 2013, Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity, J. Allergy Clin. Immunol., 132, 170, 10.1016/j.jaci.2013.04.048 · DOI

200 of 215 shown

Cited by

Sorted by citations

See all 416

Metadata

Authors
Mondal, J., Pillarisetti, S., Junnuthula, V., Saha, M., Hwang, S. R., Park, I.-K., & Lee, Y.-K.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2023-01
Volume
353
Pages
1127-1149
ISSN
0168-3659
DOI
10.1016/j.jconrel.2022.12.027
Cited by
416
References
17
Language
en
Licence
Funders
  • Ministry of Education (2020R1A2C2005620, 2020R1A5A2031185, 2021R1A6A1A03046418)
  • Ministry of Science, ICT and Future Planning (2021R1A2C2095113)
  • National Research Foundation of Korea
  • Chonnam National University Hwasun Hospital

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review